Zotiraciclib

PreclinicalSmall molecule

NNational Cancer Institute (NCI)

Zotiraciclib is one of 78 small molecule programs targeting Anaplastic Astrocytoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anaplastic AstrocytomaActive, not recruiting

Malignant GliomaActive, not recruiting

Brain TumorRecruiting

Anaplastic AstrocytomaPhase 1/Phase 2

Active, not recruiting

Malignant GliomaPhase 1/Phase 2

Active, not recruiting

Brain TumorPreclinical

Recruiting

Competition

Competitive Landscape

199 competitors in Malignant Glioma

#DrugCompanyPhaseTrials

Bicnu

MMelissa K Accordino

Phase 3

9 2

Ceenu

AAzurity Pharmaceuticals

Phase 3

4 3

Oncovin

EEastern Cooperative Oncology Group

Phase 3

1 4

Camptosar

Pfizer

Phase 2

3 5

Thalomid

Bristol-Myers Squibb

Phase 2

3 6

Avastin

BBio-Thera Solutions

Phase 2

12 7

Sutent

Pfizer

Phase 2

2 8

Zofran

Novartis

Phase 2

2 9

Leukine

Sanofi

Phase 2

2 10

Imjudo

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

PreclinicalRecruiting

Brain Tumor

NCT05588141

Clinical

Trials by Indication[1]

Anaplastic Astrocytoma1 trial

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT02942264·53 enrolled

Brain Tumor1 trial

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05588141·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Zotiraciclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zotiraciclib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zotiraciclib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Cancer Institute (NCI)

Zotiraciclib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Anaplastic Astrocytoma1 trial

Brain Tumor1 trial

References

Drug Info

Quick Facts

Related News